TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition
Biochemical and Biophysical Research Communications · 2025-08 · 775 · 152146
DOI: 10.1016/j.bbrc.2025.152146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2025-08. Verfasst von Ma Carmela Dela Cruz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA; Biological Models Laboratory, Department of Biochemistry and Molecular B…. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Drug Resistance, Neoplasm, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Philippines Council for Health Research and Development, Department of Science and Technology, Ministry of Science and Technology, India, National Institutes of Health.
Abstract (Originalsprache)
Targeted therapies using EGFR-TKIs are fundamental treatment options for cases of lung adenocarcinoma harboring sensitizing mutations in EGFR. However, tumor progression to acquired resistance significantly hinders long-term efficacy. While the involvement of transcription factors in EGFR-TKI resistance has been extensively investigated, the contribution of transcriptional co-repressors like Transducin-Like Enhancer of Split 1 (TLE1) remains largely unexplored. This study identifies TLE1 as a mediator of insensitivity to EGFR-TKI treatment in lung adenocarcinoma positive for EGFR mutation. Analysis of patient data indicated that elevated TLE1 level was associated with unfavorable survival outcomes among patients with EGFR-mutant LUAD, underscoring its clinical significance. In vitro, specifically in PC9 and HCC827 cells, exogenous TLE1 expression promoted epithelial-mesenchymal transition (EMT) and reduced cellular response to the EGFR-TKIs gefitinib and osimertinib. Conversely, sole downregulation of endogenous TLE1 expression partially restored drug sensitivity in PC9GR and HCC827GR acquired resistance cell line models. At a mechanistic level, TLE1 functions as a co-repressor, interacting with ZEB1 to suppress E-cadherin expression, a key EMT marker, thereby facilitating resistance. This paper provides first evidence of TLE1 driven EMT-associated failure of EGFR-TKI treatment particularly in EGFR-mutant LUAD through its co-repressor activity. These results underscore the previously underappreciated role of transcriptional co-repressors in therapeutic resistance and position TLE1 as a promising prognostic and therapeutic target. Interventions targeting the TLE1-ZEB1 interaction may represent a new approach to mitigate EGFR-TKI resistance and improve outcomes for patients with EGFR-mutant LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA; Biological Models Laboratory, Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Man…
- Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA.
- Biological Models Laboratory, Department of Biochemistry and Molecular Biology, College of Medicine, University of the Philippines Manila, Manila City, Philippines.
- Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA. Electronic address: hbiliran@xula.edu.
Förderung
- Philippines Council for Health Research and Development
- Department of Science and Technology, Ministry of Science and Technology, India
- National Institutes of Health
Zitieren
APA
Dela Cruz, M. C., Yao, X., Roberts, N., Iheukwumere, P., Carmouche, A., Medina, P. M., & Biliran, H. (2025). TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition. Biochemical and Biophysical Research Communications, 775, 152146. https://doi.org/10.1016/j.bbrc.2025.152146
Vancouver
Dela Cruz MC, Yao X, Roberts N, Iheukwumere P, Carmouche A, Medina PM, et al. TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition. Biochemical and Biophysical Research Communications. 2025;775:152146. doi:10.1016/j.bbrc.2025.152146
BibTeX
@article{DelaCruz2025,
author = {Dela Cruz, Ma Carmela and Yao, Xin and Roberts, Nasir and Iheukwumere, Prince and Carmouche, Alana and Medina, Paul Mark and Biliran, Hector},
title = {TLE1 drives EGFR-TKI resistance in EGFR-mutant lung adenocarcinoma through epithelial to mesenchymal transition},
journal = {Biochemical and Biophysical Research Communications},
year = {2025},
volume = {775},
pages = {152146},
doi = {10.1016/j.bbrc.2025.152146}
}
EUVIMED